Peter John Ratcliffe - 23 May 2024 Form 4 Insider Report for Immunocore Holdings plc (IMCR)

Reporting relationship: Director
Issuer ticker: IMCR
Reported as of: 23 May 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 28 May 2024, 16:15:15 UTC
Prior SEC filing: 02 Jan 2024
Next SEC filing: 19 May 2025
Source filing: View source filing
Reporting owner signature: /s/ Lily Hepworth, Attorney-in-Fact

Key filing fact

Peter John Ratcliffe filed Form 4 for Immunocore Holdings plc (IMCR) on 28 May 2024.

Key facts

This page summarizes Peter John Ratcliffe's Form 4 filing for Immunocore Holdings plc (IMCR).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 28 May 2024, 16:15.

Change

Previous filing in this sequence was filed on 02 Jan 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IMCR transaction Derivative

Share Option (Right to Buy)

Award

Transaction value: $0
Shares: +14,534
Change %
Price: $0.000000
Shares after: 14,534
Date: 23 May 2024
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 14,534
Exercise price: $50.47
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares subject to the option award shall vest at the earlier of (i) May 23, 2025 and (ii) the day immediately prior to the date of our next annual general meeting, subject to the Reporting Person's continuous service through such vesting date.